DOCSLIB.ORG

B Members: the Dark Side of NF-Κb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B Members: the Dark Side of NF-Κb Oncogene (2015) 34, 2279–2287 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Non-conventional functions for NF-κB members: the dark side of NF-κB L Espinosa, P Margalef and A Bigas NF-κB pathway exerts an essential function in the regulation of the immune response, which has been the nucleus of numerous studies for the past 25 years. Both activation of the pathway and termination of the NF-κB response are tightly regulated events, which is essential to prevent exacerbated inflammatory responses. Thus, alterations in NF-κB regulatory elements might result in tissue damage and cancer in different systems. In addition, several of the proteins involved in NF-κB regulation display additional, and much less studied, functions that connect with specific NF-κB-unrelated pathways. Many of these pathways are in turn regulators of particular physiologic and/or pathologic responses. Which are the principal non-conventional functions that have been identified for specific NF-κB elements, how they connect with other signaling pathways and what is their potential impact on cancer is the focus of this review. Oncogene (2015) 34, 2279–2287; doi:10.1038/onc.2014.188; published online 30 June 2014 INTRODUCTION multiple stimuli such as TNF-α, interleukin-1β (IL1β), pathogen- More than 25 years ago, NF-κB was discovered in the laboratory of associated molecular patterns and others. Association of TNFα Sen and Baltimore.1 After that, five members of the transcription with its receptor (TNFR1) localized at the cell surface leads to the factor NF-κB have been identified in mammals: RelA (p65), RelB recruitment of the adaptor proteins TRADD, TRAF2, cIAP1, cIAP2 and c-Rel, the p50 precursor NF-κB1 (p105) and NF-κB2 (p100) that and RIP1. Assembly of this complex to the TNFR1 promotes RIP1 can be processed to p52. These family of proteins are polyubiquitination by non-degradative K63-linked polyubiquitin characterized by a highly conserved Rel homology domain, which chains, which then serve as docking sites for TAB2 and TAB3, mediates dimerization, DNA binding and their interaction with which are essential components of the TAK1 complex. The IKK inhibitor of κB(IκB) proteins.2,3 Targeted disruption of different complex is also recruited to the TNFR1 signalosome through NF-κB family genes in mice has revealed a certain degree of NEMO, which recognizes the ubiquitinated RIP1, thus bringing redundancy,4,5 likely due to their ability to form homo- and TAK1 and IKK into close proximity, and also facilitating IKK heterodimers that recognize a common DNA sequence motif, the phosphorylation by TAK1. Recently, a novel ubiquitin E3 ligase κB consensus.6 One of the more striking phenotypes is that complex, LUBAC, was found to be recruited to TNFR1 in response obtained following p65 deletion, which leads to embryonic death to stimulation and required for NF-κB activation.16 LUBAC by massive tumor necrosis factor-α (TNFα)-induced apoptosis in (composed of HOIP, HOIL and Sharpin) and Ubc5 catalyze linear the liver.7 polyubiquitination of NEMO in vitro,17 and depletion of a single – Activation of different NF-κB dimers (except for p52:RelB) is LUBAC element impairs NF-κB activation.18 20 In general, different controlled by IκB proteins, which prevent nuclear entry and DNA E3 ubiquitin ligases participate of the TNFR1 signaling by binding through masking the nuclear localization signal of Rel promoting non-degradative ubiquitination of specific NF-κB proteins. A critical regulatory event in NF-κB signaling is the site- elements that is counteracted by the activity of the CYLD- and – specific phosphorylation of IκB(α, β and ε) by the IκB kinase (IKK) A20-deubiquitinating enzymes.21 26 complex, which results in their subsequent polyubiquitination and Other stimuli such as BAFF or the CD40 ligand are involved in – proteasomal degradation. Then, IκBs are rapidly resynthesized in the activation of the alternative NF-κB pathway.27 31 TRAF2, TRAF3 response to NF-κB activation, leading to a robust negative and cIAP1/2 inhibit alternative NF-κB in resting cells by targeting regulation of the pathway that is crucial for the proper termination the NIK kinase for ubiquitin-dependent degradation.32 Upon CD40 of the NF-κB response.8–10 or BAFF-R activation, TRAF2 ubiquitinates and activates cIAP1– The IKK complex consists of the IKKα and IKKβ kinases, and the cIAP2, which in turn induce a degradative K48-linked polyubiqui- regulatory subunit IKKγ, also called NEMO (for NF-κB essential tination of TRAF3. In the absence of TRAF3, newly synthesized NIK modulator).11–15 Activation of IKKα and IKKβ is triggered by fails to associate with the TRAF2–cIAP1–cIAP2 complex. This allows phosphorylation at specific residues (serines 176–180 for IKKα and NIK accumulation and its activation by autophosphorylation. Then, 177–181 for IKKβ)11 that is catalyzed by NF-κB-inducing kinase activated NIK phosphorylates IKKα,33,34 thus promoting p100 (NIK) and transforming growth factor-β activated kinase 1 ( TAK1), phosphorylation, association with SCFβTrCP and its subsequent respectively, which determine the signaling through alternative or proteasome-dependent processing into p52.35 Generation of canonical NF-κB pathway. Canonical NF-κB can be induced by mature p52 by IKKα is IKKβ and NEMO independent,27 and is Stem Cells and Cancer Research Laboratory, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. Correspondence: Dr L Espinosa, Stem Cells and Cancer Research Laboratory, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Dr Aiguader 88, Barcelona 08003, Spain. E-mail: [email protected] Received 16 April 2014; revised 19 May 2014; accepted 23 May 2014; published online 30 June 2014 Non-conventional functions for NF-κB members L Espinosa et al 2280 sufficient to promote nuclear translocation of the p52/RelB dimer impaired IL-12 activation, suggesting that this nuclear IKKα leading to alternative NF-κB signaling.36,37 function is also dependent on NEMO.44 On the other hand, phosphorylation of histone H3 by IKKα is not restricted to NF-κB- regulated gene promoters. For example, IKKα mediates the NON-CONVENTIONAL FUNCTIONS FOR IKKα activation of c-fos, a mitogenic transducer, in response to As mentioned, although most IKKα is located in the cytoplasm as epidermal growth factor, and in the absence of NF-κB part of the IKK complex, its kinase activity is not essential for the activation.45 IKKα also promotes transcription of hormone- activation of canonical NF-κB by most proinflammatory responsive genes in breast cancer cells through its direct stimuli.38,39 However, its activity is primarily required for the interaction with the nuclear hormone coactivator SRC-3.46 activation of the alternative pathway, which participates on Specifically, IKKα facilitates the recruitment of ERα and SRC-3 to adaptative immunity and lymphoid organogenesis.40 On the the cyclin D1 and c-myc gene promoters, leading to gene other hand, several stimuli promote IKKα to accumulate in the transcription, whereas reduction of IKKβ, p65, c-Rel, or p100 levels nuclear compartment of the cells, where it phosphorylates specific do not have any effect. IKKα-dependent activation of these genes substrates resulting in particular outcomes (Figure 1). results in increased proliferation of breast cancer cells. In T cells, IKKα regulates IL-2, interferon-γ and IL-17 transcription in the T helper type 17 lineage, a subset of T cells with a prominent role PHOSPHORYLATION OF HISTONE H3 BY IKKα in many inflammatory diseases. A kinase dead form of IKKα failed The first indication that IKKα exerted additional nuclear functions to promote inflammatory-related transcription and blocked the was the demonstration that IKKα accumulates in the nucleus and development of autoimmune encephalomyelitis.47 Physiologically, phosphorylates serine 10 of histone H3 at NF-κB-dependent IKKα is present in the nucleus of CD4+ T cells and recruited to the promoters following TNFα stimulation (for a review, see Il17a promoter upon T helper type 17 differentiation, thus Anest et al.41 and Yamamoto et al.42). Thus, IKKα-deficient cells promoting histone H3 phosphorylation and a transcriptional do not show any defect on IκBα phosphorylation or degradation, activation of the locus, in an NF-κB-independent manner. but they display a reduced capacity to activate NF-κB-dependent transcription (i.e. IκBα or IL-8 genes). Mechanistically, IKKα not only phosphorylates histone H3 but it also interacts with PHOSPHORYLATION OF NUCLEAR COREPRESSORS the coactivator CBP facilitating histone acetylation and Other substrates for IKKα kinase are the silencing mediator for chromatin relaxation. A similar function is exerted by IKKα in retinoic acid and thyroid hormone receptor (SMRT) and the lipopolysaccharide-treated macrophages. However, lipopolysac- nuclear corepressor (NCoR). Phosphorylation of SMRT by IKKα at charide not only affect IKKα localization but also that NIK shows serine 2410 induces its dissociation from the chromatin, and is a nuclear distribution in endotoxin-treated macrophages, associated prerequisite for the activation of NF-κB-dependent genes, such as with an increase in the levels of IKKα and histone H3 ciap-2 and IL-8, following laminin attachment in androgen- phosphorylation. Reduction of NIK levels by small interfering insensitive DU145 prostate cancer cells.48 In basal conditions, RNA reduced IKKα activity and histone H3 phosphorylation in SMRT and HDAC3 are bound to the chromatin together with p50 these cells.43 Patients with mutations in NEMO show reduced homodimers leading to basal gene repression. Upon stimulation, levels of phosphorylated (S10) histone H3 associated with IKKα-mediated phosphorylation of SMRT initiates transcriptional Figure 1. IKKα kinase activity is exerted on both cytoplasmic and nuclear substrates. The schematic diagram represents a summary of known non-NF-κB substrates that are phosphorylated by IKKα under physiologic conditions.
Load more

Recommended publications
  • Progesterone Receptor Coregulators As Factors Supporting the Function of the Corpus Luteum in Cows
    G C A T T A C G G C A T genes Article Progesterone Receptor Coregulators as Factors Supporting the Function of the Corpus Luteum in Cows Robert Rekawiecki * , Karolina Dobrzyn, Jan Kotwica and Magdalena K. Kowalik Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, Tuwima 10, 10–747 Olsztyn, Poland; [email protected] (K.D.); [email protected] (J.K.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +48-89-539-31-17 Received: 5 July 2020; Accepted: 7 August 2020; Published: 12 August 2020 Abstract: Progesterone receptor (PGR) for its action required connection of the coregulatory proteins, including coactivators and corepressors. The former group exhibits a histone acetyltransferase (HAT) activity, while the latter cooperates with histone deacetylase (HDAC). Regulations of the coregulators mRNA and protein and HAT and HDAC activity can have an indirect effect on the PGR function and thus progesterone (P4) action on target cells. The highest mRNA expression levels for the coactivators—histone acetyltransferase p300 (P300), cAMP response element-binding protein (CREB), and steroid receptor coactivator-1 (SRC-1)—and nuclear receptor corepressor-2 (NCOR-2) were found in the corpus luteum (CL) on days 6 to 16 of the estrous cycle. The CREB protein level was higher on days 2–10, whereas SRC-1 and NCOR-2 were higher on days 2–5. The activity of HAT and HDAC was higher on days 6–10 of the estrous cycle. All of the coregulators were localized in the nuclei of small and large luteal cells.
    [Show full text]
  • Identification of a Different-Type Homeobox Gene, Barhi, Possibly Causing Bar (B) and Om(Ld) Mutations in Drosophila
    Proc. Nati. Acad. Sci. USA Vol. 88, pp. 4343-4347, May 1991 Genetics Identification of a different-type homeobox gene, BarHI, possibly causing Bar (B) and Om(lD) mutations in Drosophila (compound eye/homeodomain/morphogenesis/malformation/M-repeat) TETSUYA KOJIMA, SATOSHI ISHIMARU, SHIN-ICHI HIGASHUIMA, Eui TAKAYAMA, HIROSHI AKIMARU, MASAKI SONE, YASUFUMI EMORI, AND KAORU SAIGO* Department of Biophysics and Biochemistry, Faculty of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan Communicated by Melvin M. Green, January 25, 1991 ABSTRACT The Bar mutation B of Drosophila melano- the initial periodicity. A class of mutations including Bar (B) gaster and optic morphology mutation Om(JD) of Drosophila may also be intimately related to early events (9). For ananassae result in suppression of ommatidium differentiation clarification of this point, examination was first made of at the anterior portion of the eye. Examination was made to possible determinant genes for the Bar mutation B of Dro- determine the genes responsible for these mutations. Both loci sophila melanogaster (10) and optic morphology mutation were found to share in common a different type of homeobox Om(JD) of Drosophila ananassae (11), in both of which gene, which we call "BarH1." Polypeptides encoded by D. ommatidium differentiation is suppressed in the anterior melanogaster and D. ananassae BarHl genes consist of543 and portion ofthe eye. Both locit were found to share in common 604 amino acids, respectively, with homeodomains identical in a different type of homeobox gene, called BarH1, which sequence except for one amino acid substitution. A unique encodes a polypeptide of Mr - 60,000.
    [Show full text]
  • Etiology of Hormone Receptor–Defined Breast Cancer: a Systematic Review of the Literature
    1558 Cancer Epidemiology, Biomarkers & Prevention Review Etiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the Literature Michelle D. Althuis, Jennifer H. Fergenbaum, Montserrat Garcia-Closas, Louise A. Brinton, M. Patricia Madigan, and Mark E. Sherman Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland Abstract Breast cancers classified by estrogen receptor (ER) and/ negative tumors. Postmenopausal obesity was also or progesterone receptor (PR) expression have different more consistently associated with increased risk of clinical, pathologic, and molecular features. We exam- hormone receptor–positive than hormone receptor– ined existing evidence from the epidemiologic litera- negative tumors, possibly reflecting increased estrogen ture as to whether breast cancers stratified by hormone synthesis in adipose stores and greater bioavailability. receptor status are also etiologically distinct diseases. Published data are insufficient to suggest that exoge- Despite limited statistical power and nonstandardized nous estrogen use (oral contraceptives or hormone re- receptor assays, in aggregate, the critically evaluated placement therapy) increase risk of hormone-sensitive studies (n = 31) suggest that the etiology of hormone tumors. Risks associated with breast-feeding, alcohol receptor–defined breast cancers may be heterogeneous. consumption, cigarette smoking, family history of Reproduction-related exposures tended to be associat-
    [Show full text]
  • Estrogen Receptor-Α Interaction with the CREB Binding Protein
    307 Estrogen receptor- interaction with the CREB binding protein coactivator is regulated by the cellular environment B M Jaber, R Mukopadhyay and C L Smith Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA (Requests for offprints should be addressed to C L Smith; Email: [email protected]) Abstract The p160 coactivators, steroid receptor coactivator-1 (SRC-1), transcriptional intermediary factor-2 (TIF2) and receptor-associated coactivator-3 (RAC3), as well as the coactivator/integrator CBP, mediate estrogen receptor- (ER)-dependent gene expression. Although these coactivators are widely expressed, ER transcriptional activity is cell-type dependent. In this study, we investigated ER interaction with p160 coactivators and CBP in HeLa and HepG2 cell lines. Basal and estradiol (E2)-dependent interactions between the ER ligand-binding domain (LBD) and SRC-1, TIF2 or RAC3 were observed in HeLa and HepG2 cells. The extents of hormone-dependent interactions were similar and interactions between each of the p160 coactivators and the ER LBD were not enhanced by 4-hydroxytamoxifen in either cell type. In contrast to the situation for p160 coactivators, E2-dependent interaction of the ER LBD with CBP or p300 was detected in HeLa but not HepG2 cells by mammalian two-hybrid and coimmunoprecipitation assays, indicating that the cellular environment modulates ER-CBP/p300 interaction. Furthermore, interactions between CBP and p160 coactivators are much more robust in HeLa than HepG2 cells suggesting that poor CBP-p160 interactions are insufficient to support ER–CBP–p160 ternary complexes important for nuclear receptor–CBP interactions. Alterations in p160 coactivators or CBP expression between these two cell types did not account for differences in ER–p160–CBP interactions.
    [Show full text]
  • Understanding Nuclear Receptor Form and Function Using Structural Biology
    F RASTINEJAD and others Understanding NR form 51:3 T1–T21 Thematic Review and function Understanding nuclear receptor form and function using structural biology Correspondence Fraydoon Rastinejad, Pengxiang Huang, Vikas Chandra and Sepideh Khorasanizadeh should be addressed to F Rastinejad Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, Orlando, Email Florida 32827, USA frastinejad@ sanfordburnham.org Abstract Nuclear receptors (NRs) are a major transcription factor family whose members selectively Key Words bind small-molecule lipophilic ligands and transduce those signals into specific changes in " nuclear receptors gene programs. For over two decades, structural biology efforts were focused exclusively on " steroid hormones the individual ligand-binding domains (LBDs) or DNA-binding domains of NRs. These " transcription factors analyses revealed the basis for both ligand and DNA binding and also revealed receptor " gene regulation conformations representing both the activated and repressed states. Additionally, " metabolism crystallographic studies explained how NR LBD surfaces recognize discrete portions of transcriptional coregulators. The many structural snapshots of LBDs have also guided the development of synthetic ligands with therapeutic potential. Yet, the exclusive structural focus on isolated NR domains has made it difficult to conceptualize how all the NR polypeptide segments are coordinated physically and functionally in the context of receptor Journal of Molecular Endocrinology quaternary architectures. Newly emerged crystal structures of the peroxisome proliferator- activated receptor-g–retinoid X receptor a (PPARg–RXRa) heterodimer and hepatocyte nuclear factor (HNF)-4a homodimer have recently revealed the higher order organizations of these receptor complexes on DNA, as well as the complexity and uniqueness of their domain–domain interfaces.
    [Show full text]
  • Nuclear Hormone Receptor Antagonism with AP-1 by Inhibition of the JNK Pathway
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway Carme Caelles,1 Jose´M. Gonza´lez-Sancho, and Alberto Mun˜oz2 Instituto de Investigaciones Biome´dicas, Consejo Superior de Investigaciones Cientı´ficas, E-28029 Madrid, Spain The activity of c-Jun, the major component of the transcription factor AP-1, is potentiated by amino-terminal phosphorylation on serines 63 and 73 (Ser-63/73). This phosphorylation is mediated by the Jun amino-terminal kinase (JNK) and required to recruit the transcriptional coactivator CREB-binding protein (CBP). AP-1 function is antagonized by activated members of the steroid/thyroid hormone receptor superfamily. Recently, a competition for CBP has been proposed as a mechanism for this antagonism. Here we present evidence that hormone-activated nuclear receptors prevent c-Jun phosphorylation on Ser-63/73 and, consequently, AP-1 activation, by blocking the induction of the JNK signaling cascade. Consistently, nuclear receptors also antagonize other JNK-activated transcription factors such as Elk-1 and ATF-2. Interference with the JNK signaling pathway represents a novel mechanism by which nuclear hormone receptors antagonize AP-1. This mechanism is based on the blockade of the AP-1 activation step, which is a requisite to interact with CBP. In addition to acting directly on gene transcription, regulation of the JNK cascade activity constitutes an alternative mode whereby steroids and retinoids may control cell fate and conduct their pharmacological actions as immunosupressive, anti-inflammatory, and antineoplastic agents.
    [Show full text]
  • Biochem II Signaling Intro and Enz Receptors
    Signal Transduction What is signal transduction? Binding of ligands to a macromolecule (receptor) “The secret life is molecular recognition; the ability of one molecule to “recognize” another through weak bonding interactions.” Linus Pauling Pleasure or Pain – it is the receptor ligand recognition So why do cells need to communicate? -Coordination of movement bacterial movement towards a chemical gradient green algae - colonies swimming through the water - Coordination of metabolism - insulin glucagon effects on metabolism -Coordination of growth - wound healing, skin. blood and gut cells Hormones are chemical signals. 1) Every different hormone binds to a specific receptor and in binding a significant alteration in receptor conformation results in a biochemical response inside the cell 2) This can be thought of as an allosteric modification with two distinct conformations; bound and free. Log Dose Response • Log dose response (Fractional Bound) • Measures potency/efficacy of hormone, agonist or antagonist • If measuring response, potency (efficacy) is shown differently Scatchard Plot Derived like kinetics R + L ó RL Used to measure receptor binding affinity KD (KL – 50% occupancy) in presence or absence of inhibitor/antagonist (B = Receptor bound to ligand) 3) The binding of the hormone leads to a transduction of the hormone signal into a biochemical response. 4) Hormone receptors are proteins and are typically classified as a cell surface receptor or an intracellular receptor. Each have different roles and very different means of regulating biochemical / cellular function. Intracellular Hormone Receptors The steroid/thyroid hormone receptor superfamily (e.g. glucocorticoid, vitamin D, retinoic acid and thyroid hormone receptors) • Protein receptors that reside in the cytoplasm and bind the lipophilic steroid/thyroid hormones.
    [Show full text]
  • Role of Estrogen Receptor in Breast Cancer Cell Gene Expression
    4046 MOLECULAR MEDICINE REPORTS 13: 4046-4050, 2016 Role of estrogen receptor in breast cancer cell gene expression YABING ZHENG1, XIYING SHAO1, YUAN HUANG1, LEI SHI1, BO CHEN2, XIAOJIA WANG1, HONGJIAN YANG3, ZHANHONG CHEN1 and XIPING ZHANG3 Departments of 1Medical Oncology (Breast), 2Pathology and 3Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China Received April 28, 2015; Accepted February 23, 2016 DOI: 10.3892/mmr.2016.5018 Abstract. The aim of the present study was to establish the Europe in 2012, and the number of breast cancer-associated underlying regulatory mechanism of estrogen receptor (ER) mortalities is 131,000 (6). Furthermore, breast cancer is in breast cancer cell gene expression. A gene expression the most common cause of cancer-associated mortality in profile accession( no. GSE11324) was downloaded from the females. Therefore, it is essential to understand its molecular Gene Expression Omnibus (GEO) database. Differentially mechanism and develop more effective therapeutic methods expressed genes (DEGs) from an estrogen treatment group and for breast cancer treatment. a control group were identified. Chromatin immunoprecipita- The estrogen receptor (ER) is critical in determining the tion with high-throughput sequencing data (series GSE25710) phenotype of human breast cancers and is one of the most was obtained from the GEO for the ER binding sites, and important therapeutic targets (7). Furthermore, certain studies binding and expression target analysis was performed. A total have suggested that activation of ER is responsible for various of 3,122 DEGs were obtained and ER was demonstrated to biological processes, including cell growth and differentia- exhibit inhibition and activation roles during the regulation tion, and programmed cell death (8,9).
    [Show full text]
  • Understanding a Breast Cancer Diagnosis Breast Cancer Grade and Other Tests
    cancer.org | 1.800.227.2345 Understanding a Breast Cancer Diagnosis Breast Cancer Grade and Other Tests Doctors use information from your breast biopsy to learn a lot of important things about the exact kind of breast cancer you have. ● Breast Cancer Grades ● Breast Cancer Ploidy and Cell Proliferation ● Breast Cancer Hormone Receptor Status ● Breast Cancer HER2 Status ● Breast Cancer Gene Expression Tests ● Understanding Your Pathology Report Stages and Outlook (Prognosis) If you have been diagnosed with breast cancer, tests will be done to find out the extent (stage) of the cancer. The stage of a cancer helps determine how serious the cancer is and how best to treat it. ● Imaging Tests to Find Out if Breast Cancer Has Spread ● Breast Cancer Stages ● Breast Cancer Survival Rates Questions to Ask About Your Breast Cancer You can take an active role in your breast cancer care by learning about your cancer and its treatment and by asking questions. Get a list of key questions here. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 ● Questions to Ask Your Doctor About Breast Cancer Connect with a breast cancer survivor Reach To Recovery The American Cancer Society Reach To Recovery® program connects people facing breast cancer – from diagnosis through survivorship – with trained volunteers who are breast cancer survivors. Our volunteers provide one-on-one support through our website and mobile app to help those facing breast cancer cope with diagnosis, treatment, side effects, and more. Breast Cancer Grades Knowing a breast cancer’s grade is important to understand how fast it’s likely to grow and spread.
    [Show full text]
  • The NF-KB Pathway and Endocrine Therapy Resistance in Breast Cancer
    26 6 Endocrine-Related P Khongthong et al. Nuclear factor kappa B and 26:6 R369–R380 Cancer breast cancer REVIEW The NF-KB pathway and endocrine therapy resistance in breast cancer Phungern Khongthong, Antonia K Roseweir and Joanne Edwards Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of MVLS, University of Glasgow, Glasgow, UK Correspondence should be addressed to J Edwards: [email protected] Abstract Breast cancer is a heterogeneous disease, which over time acquires various adaptive Key Words changes leading to more aggressive biological characteristics and development of f NF-KB treatment resistance. Several mechanisms of resistance have been established; however, f endocrine therapy due to the complexity of oestrogen receptor (ER) signalling and its crosstalk with other resistance signalling networks, various areas still need to be investigated. This article focusses f breast cancer on the role of nuclear factor kappa B (NF-KB) as a key link between inflammation and cancer and addresses its emerging role as a key player in endocrine therapy resistance. Understanding the precise mechanism of NF-KB-driven endocrine therapy resistance provides a possible opportunity for therapeutic intervention. Endocrine-Related Cancer (2019) 26, R369–R380 Introduction Oestrogen receptor α-positive (ER+) breast cancer respond to endocrine therapies as a result of either de constitutes more than 70% of all breast cancers novo or acquired resistance (Liu et al. 2017). (Cardoso et al. 2012). Both early and metastatic disease Many comprehensive reviews (Riggins et al. 2007, are treated effectively with endocrine therapies, which Clarke et al. 2009, Zhao & Ramaswamy 2014, Liu et al.
    [Show full text]
  • Inflammation and NF-B Signaling in Prostate Cancer
    cells Review Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications Jens Staal 1,2 ID and Rudi Beyaert 1,2,* ID 1 VIB-UGent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, 9052 Ghent, Belgium 2 Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium * Correspondence: [email protected]; Tel.: +32-9-3313770 Received: 31 July 2018; Accepted: 27 August 2018; Published: 29 August 2018 Abstract: Prostate cancer is a highly prevalent form of cancer that is usually slow-developing and benign. Due to its high prevalence, it is, however, still the second most common cause of death by cancer in men in the West. The higher prevalence of prostate cancer in the West might be due to elevated inflammation from metabolic syndrome or associated comorbidities. NF-κB activation and many other signals associated with inflammation are known to contribute to prostate cancer malignancy. Inflammatory signals have also been associated with the development of castration resistance and resistance against other androgen depletion strategies, which is a major therapeutic challenge. Here, we review the role of inflammation and its link with androgen signaling in prostate cancer. We further describe the role of NF-κB in prostate cancer cell survival and proliferation, major NF-κB signaling pathways in prostate cancer, and the crosstalk between NF-κB and androgen receptor signaling. Several NF-κB-induced risk factors in prostate cancer and their potential for therapeutic targeting in the clinic are described. A better understanding of the inflammatory mechanisms that control the development of prostate cancer and resistance to androgen-deprivation therapy will eventually lead to novel treatment options for patients.
    [Show full text]
  • Estrogen and Progesterone Regulate Radiation-Induced P53 Activity in Mammary Epithelium Through TGF-B-Dependent Pathways
    Oncogene (2005) 24, 6345–6353 & 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-b-dependent pathways Klaus A Becker1,2, Shaolei Lu1,2, Ellen S Dickinson2, Karen A Dunphy1,2, Lesley Mathews1,3, Sallie Smith Schneider1,3 and D Joseph Jerry*,1,2 1Molecular and Cellular Biology Program, University of Massachusetts, Amherst, MA 01003, USA; 2Paige Laboratory, Department of Veterinary and Animal Sciences, University of Massachusetts, 161 Holdsworth Way, Amherst, MA 01003, USA; 3Baystate Medical Center/UMass Biomedical Research Institute, Springfield, MA 01099, USA DNA damage normally induces p53 activity, but responses hormone human chorionic gonadotropin enhance radia- to ionizing radiation in the mammary epithelium vary tion-induced apoptosis in mouse mammary epithelium among developmental stages. The following studies through activation of p53 (Kuperwasser et al., 2000; examined the hormones and growth factors that regulate Sivaraman et al., 2001; Minter et al., 2002). As these radiation-responsiveness of p53 in mouse mammary hormones have also been shown to prevent carcinogen- epithelium. Immunoreactive p21/WAF1 and TUNEL induced mammary tumors (Russo et al., 1990; Sivaraman staining were used as indicators of p53 activity following et al., 1998), it was proposed that regulation of p53 exposure to ionizing radiation. In ovariectomized mice, activity may mediate the protective effects of these radiation-induced accumulation of p21/WAF1 was mini- hormones in the mammary epithelium. The absence of mal in the mammary epithelial cells (o1%). Systemic the parity-induced protection from tumors in p53- injections of estrogen and progesterone (E þ P) for 72 h deficient mammary tissues (Medina et al., 2003) provided were necessary to recover maximal expression of p21/ direct evidence that the p53 pathway mediates the WAF1 following ionizing radiation (55%).
    [Show full text]